- Home
- Healthcare professionals
- ACE Clinical Guidances (ACGs)
- Initiating basal insulin in type 2 diabetes mellitus
Published
Initiating basal insulin in type 2 diabetes mellitus
Condition
Endocrine and metabolic
Guidance type
ACG
29 November 2024
Published on 20 Nov 2017
Last Updated on 29 Nov 2024
This ACE Clinical Guidance (ACG) highlights the importance of not delaying insulin therapy for patients with type 2 diabetes mellitus and offers a practical guide on initiating basal insulin. It also provides evidence-based practice points on how to prevent and manage hypoglycaemia. First published in 2017, this ACG been updated in 2024 to reflect recent changes in insulin product availability and incorporate the latest evidence where relevant.
Download the ACG
Initiating basal insulin in type 2 diabetes mellitus (Nov 2024) [PDF]
Registered doctors, pharmacists and nurses may claim 1 Continuing Medical Education (CME)/Continuing Professional Education (CPE) point under category 3A/ category V-B for reading each ACG.
ACG recommendations
Start basal insulin if glycaemic targets are not met despite optimal treatment with non-insulin T2DM medications.
Review concomitant T2DM medications when starting basal insulin and continue them at the current or lower dose where appropriate.
Educate patients and their caregivers on how to use insulin safely and effectively, including how to prevent and manage hypoglycaemia.
ACG references
Initiating basal insulin in type 2 diabetes mellitus references (Nov 2024) [PDF]
Feedback
Click here to give us feedback on this ACG.